Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP lessened its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 35.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 70,462 shares of the medical equipment provider's stock after selling 38,671 shares during the quarter. Bridgewater Associates LP owned 0.10% of Lantheus worth $7,733,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Farallon Capital Management LLC increased its position in shares of Lantheus by 53.7% during the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock worth $182,999,000 after acquiring an additional 796,000 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Lantheus by 1.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider's stock worth $99,525,000 after acquiring an additional 19,071 shares during the last quarter. Swedbank AB increased its position in shares of Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider's stock worth $79,266,000 after acquiring an additional 125,843 shares during the last quarter. Boston Partners increased its position in shares of Lantheus by 21.2% during the first quarter. Boston Partners now owns 681,281 shares of the medical equipment provider's stock worth $42,696,000 after acquiring an additional 119,156 shares during the last quarter. Finally, LSV Asset Management increased its position in shares of Lantheus by 27.9% during the second quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider's stock worth $51,462,000 after acquiring an additional 139,647 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Analysts Set New Price Targets

LNTH has been the subject of several research analyst reports. Truist Financial reissued a "buy" rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. JMP Securities decreased their target price on Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research note on Thursday, November 7th. Finally, Redburn Atlantic began coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price for the company. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and an average price target of $122.50.

Lantheus Price Performance

Shares of NASDAQ LNTH traded down $1.00 during midday trading on Friday, hitting $89.27. 548,640 shares of the company's stock were exchanged, compared to its average volume of 1,020,763. The stock's 50 day moving average price is $101.76 and its 200-day moving average price is $97.04. The firm has a market cap of $6.21 billion, a P/E ratio of 15.02 and a beta of 0.51. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.